7 Analysts Assess Emergent BioSolutions: What You Need To Know
Portfolio Pulse from Benzinga Insights
In the last three months, 7 analysts have published ratings on Emergent BioSolutions (NYSE:EBS), all of which are bullish. The average 12-month price target is $8.00, reflecting a 5.68% increase from the previous target of $7.57. Despite a 25.11% decline in revenue over the past three months, analysts maintain a positive outlook.
August 16, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Emergent BioSolutions (NYSE:EBS) has received 7 bullish ratings from analysts in the last three months, with an average price target of $8.00, up 5.68% from the previous target. Despite a 25.11% decline in revenue, analysts maintain a positive outlook.
The unanimous bullish ratings from analysts and the increased price target suggest a positive short-term outlook for EBS. However, the significant revenue decline and high debt-to-equity ratio may pose risks.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100